Comprehensive treatment of malignant pleural mesothelioma new method

Malignant pleural mesothelioma (MPM) is a substantive, local invasive tumors, and is closely related to asbestos exposure. If untreated, its survival in 4-12 months. The tumor on the poor response to chemotherapy and radiotherapy, surgery is the most effective treatment. Currently in the United States each year 3,000 new cases of fat in patients with MPM is expected in the United States and Europe, the incidence of the disease at the summit appeared in 2020. The prognosis of the disease depends on the time of diagnosis of the tumor stage, histological type, lymph node status and the margin. Despite the diagnosis often expected to be delayed, but early intervention therapy can improve life expectancy. Loyola University of Chicago Medical Center, Dr. Neragi-Miandoab S for the treatment of the disease were analyzed. The results showed that a single therapy for MPM to change the natural history and to no avail. As a result, medical personnel began to consider a joint operation, including radiotherapy, chemotherapy or immunotherapy, the combined treatment. Combination therapy is already showing good results, especially for epithelial tissue, the negative margin and outside the pleura of metastasis in patients with better results. Cisplatin and mitomycin C for control of distant recurrence of the tumor has a certain effect. Research also showed that cisplatin and gemcitabine, as well as the treatment of cisplatin / pemetrexed after 54Gy supporting the use of hemi-thoracic radiation therapy can improve the prognosis